Italian researchers have developed a vulnerability score to better assess survival in multiple myeloma patients. The score is based on the patient’s overall health and the presence of other diseases.

The investigators found that a high vulnerability score was associated with shorter overall survival in all patients, regardless of the patient’s age.

Based on their findings, the investigators recommend that the score be investigated further in larger prospective studies. If its usefulness is confirmed in these studies, the score could be used to personalize treatment for myeloma.

According to the Italian researchers, …

One of the first questions most of us probably ask after being diagnosed with multiple myeloma is "How long do I have?", or some derivative thereof.  For me, I think the question came right after asking what multiple myeloma is, and whether it's curable.

Perhaps it might be better to take a more philosophical approach and respond by asking "How long does anyone have?", reflecting the fact that life is a crap shoot, stuff happens, and we truly don't know when we will die.

After all, barring any knowledge of the unforeseen, …

Follow-up results from a long-term study conducted in Italy indicate that quality of response may be the most significant predictor of long-term survival in newly diagnosed multiple myeloma patients receiving a stem cell transplant.

The results also showed that hemoglobin levels and platelet counts at diagnosis were independent factors predicting for long-term survival.

“[This study] confirms the importance of achieving high-quality responses not only as a surrogate marker of progression-free survival and overall survival but also for long-term overall survival,” said Dr. Elena Zamagni, one of study’s investigators from Seragnoli Institute of …

Results from a recent French study identified several factors that predict long-term survival of patients newly diagnosed with multiple myeloma. These prognostic factors include the absence of three key chromosomal abnormalities, low beta-2 microglobulin levels in the blood, and younger age.

The three key chromosomal abnormalities that were absent in patients who survived longer were a gain in chromosome 1 (called 1q gain), a translocation from chromosome 4 to 14 (called t(4;14)), and a deletion in chromosome 17 (called del(17p)). Patients who lived longer were also younger than 55 years of age …

One of the most difficult questions in oncology is: “How long do I have to live?”

Patients often bring this up to their physicians following a diagnosis of cancer, and periodically during the course of their disease.

Of course, this is an impossible question to answer because we as physicians can seldom predict what the future holds for a particular patient. We can prob­a­bly estimate averages, but no patient is average; everyone is unique. Faced with this dilemma, each physician responds differently. Some provide the averages, some don’t.

Nevertheless, it is incredibly …

Myeloma specialists from the Czech Republic have published clinical trial results that shed further light on chromosomal abnormalities and their impact on survival in newly diag­nosed multiple myeloma patients.

Specifically, the researchers found that patients with three or more chromos­omal abnor­malities, a gain in the 1q21 region, or the trans­location t(4;14) have reduced survival compared to patients without such abnormalities.

According to the researchers, their findings highlight the importance of chromosomal abnormalities when considering treatment options for myeloma patients.

They note, however, that their findings need to be confirmed in a pro­spective, …

Since I got my myeloma diagnosis five and a half years ago, I haven’t been given to bouts of depression.

With a myeloma diagnosis, you really don’t have time to feel sorry for yourself.

I’ve tried to take in stride all the things “they” have done to me – two autologus stem cell transplants, a myriad of chemotherapy side effects, an open lung biopsy, and endless needle sticks, just to name a few.

Then there’s the prodding, probing, and testing by various doctors and specialist of all kinds.  There were spur-of-the-moment ultrasounds …